Combination immunotherapy for hepatocellular carcinoma

肝细胞癌 医学 免疫疗法 肿瘤科 内科学 癌症研究 癌症
作者
Lorenza Rimassa,Richard S. Finn,Bruno Sangro
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:79 (2): 506-515 被引量:181
标识
DOI:10.1016/j.jhep.2023.03.003
摘要

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20%, mostly without a significant overall survival (OS) benefit. Furthermore, approximately 30% of HCC exhibits intrinsic resistance to ICIs. In the absence of predictive biomarkers to identify patients likely to benefit most from immunotherapy, research has moved to exploring combinations with potential activity in broader patient populations. Basket trials, including cohorts of patients with HCC, and early phase studies tested the combination of ICIs with anti-angiogenic agents as well as the combination of two different ICIs. The promising results that were achieved provided the rationale for the following phase III trials, which tested the combination of anti-PD-1/PD-L1 antibodies with bevacizumab, or tyrosine kinase inhibitors, or anti-CTLA-4 antibodies. Positive results from the IMbrave150 trial led to the practice-changing approval of atezolizumab-bevacizumab, the first regimen to demonstrate improved survival in the front-line setting since the approval of sorafenib. More recently, the HIMALAYA trial demonstrated the superiority of durvalumab-tremelimumab (STRIDE regimen) over sorafenib, establishing a new first-line option. In contrast, inconsistent results have been achieved with combinations of ICIs and tyrosine kinase inhibitors, with only one phase III trial showing an OS benefit. The rapid evolution of the therapeutic landscape for patients with advanced HCC has left many unanswered questions that will need to be addressed by future research. These include the choice and sequencing of treatments, identification of biomarkers, combinations with locoregional therapies, and development of new immunotherapy agents. This review summarises the scientific rationale and available clinical data for combination immunotherapy in advanced HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小李完成签到,获得积分10
2秒前
shuaijiezhang完成签到,获得积分10
2秒前
充电宝应助情殇采纳,获得10
3秒前
丘比特应助tangyangzju采纳,获得10
3秒前
mix完成签到 ,获得积分10
5秒前
儒雅沛凝完成签到 ,获得积分10
5秒前
黄74185296完成签到,获得积分10
7秒前
简单的白云完成签到,获得积分10
10秒前
11秒前
chenyunxia完成签到,获得积分10
11秒前
zlx完成签到 ,获得积分10
13秒前
无忧发布了新的文献求助10
14秒前
一心完成签到,获得积分10
15秒前
平淡的寄风完成签到,获得积分0
15秒前
枕安完成签到,获得积分10
15秒前
岑夜南完成签到,获得积分10
15秒前
凌凌子完成签到 ,获得积分10
15秒前
bb完成签到,获得积分10
16秒前
aaaaa完成签到,获得积分10
16秒前
液晶屏99完成签到,获得积分10
17秒前
蜀山刀客完成签到,获得积分10
17秒前
月桂氮卓酮完成签到,获得积分10
18秒前
33完成签到 ,获得积分10
18秒前
19秒前
小王完成签到 ,获得积分10
20秒前
背带裤打篮球完成签到,获得积分0
21秒前
chiazy完成签到,获得积分10
21秒前
吴3L完成签到,获得积分10
22秒前
高兴的问儿完成签到 ,获得积分10
23秒前
情殇发布了新的文献求助10
24秒前
今天也要好好学习完成签到,获得积分10
25秒前
tsntn完成签到,获得积分10
26秒前
来一斤这种鱼完成签到 ,获得积分10
26秒前
pantio完成签到,获得积分10
27秒前
清秀服饰完成签到 ,获得积分10
28秒前
冷艳的友瑶完成签到,获得积分10
30秒前
gffh完成签到,获得积分10
31秒前
沉醉的中国钵完成签到 ,获得积分10
31秒前
nannan完成签到 ,获得积分10
32秒前
着急的千山完成签到 ,获得积分10
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513400
关于积分的说明 11167585
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875131
科研通“疑难数据库(出版商)”最低求助积分说明 804664